Abstract Immune checkpoint inhibitors (ICI) have transformed cancer treatment. However, only a minority of patients achieve a profound response. Many patients are innately resistant while others acquire resistance to ICIs….
生理学的に基づいた薬物動態モデリングは、複雑で局所的に作用するジェネリック薬の生物学的同等性（BE）評価をサポートするために使用できます。
On 2024年10月30日, we hosted our Pinnacle 21 Enterprise (P21E) User Group Meeting (UGM) in Mainz, Germany, as part of the inaugural Certara Certainty Europe customer summit. We welcomed…
In the pharmaceutical and medical devices industries, the journey from product development to market introduction is a complex one. Not only does it require significant investment in research and development,…
モデル構築者と治験担当者の協力は、モデルに基づく医薬品開発戦略の策定に不可欠です。Modelers can design an experiment so the results can be interpreted in…
Updates Full Year 2024 Financial Guidance RADNOR, PA — November 6, 2024– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today reported its financial results for the third…
The article titled “Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody,” authored by Courtney Moc Willeford, Krithika Shetty, Douglas Sheridan, and Frank…
In September 2023, the European Medicines Agency (EMA) reinstated its Policy 0070 requirement to publish all clinical studies submitted for regulatory approval. After almost five years of being offline (other…
© 2025 Certara. All Rights Reserved. | 個人情報保護
